He’s a well-respected neurologist. His colleagues think the Alzheimer’s program he’s marketing through a private company is a mix of common sense and unproven methodology.
A Trump administration maneuver allows executives leading the federal effort to keep investments in drug companies that would benefit from pandemic response.
A big culprit is something called senescent cells—and scientists are working on neutralizing them.
Mayuri Saxena’s only chance to live is through access to experimental drugs. Now Congress holds her fate in its hands.
Fewer than 10 percent of pancreatic cancer patients survive for five years.
The impudent Canadian who spent three decades in our living rooms became a nightly beacon of resilience as America poured out its love for him in his public cancer fight.
One of the virus’ biggest mysteries is how it can boost the risk of fatal blood clots. Now researchers in two study groups are exploring varying treatments with blood-thinners.